Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

Journal Articles

Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study

Blood (2014) 124 (21): 4407.

https://doi.org/10.1182/blood.V124.21.4407.4407

Published: 2014

Journal Articles

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

Mathias J. Rummel, MD, Christina Balser, MD, Ulrich Kaiser, MD, Hans Peter Böck, Martina Beate Stauch, MD, Andrea Heider, PhD, Manfred Welslau, Christoph Losem, Eckhart Weidmann, Wolfgang Blau, MD, Alexander Burchardt, MD, Jürgen Barth, Frank Kauff, PhD, Axel Hinke, PhD, Wolfram Brugger, MD

Blood (2014) 124 (21): 145.

https://doi.org/10.1182/blood.V124.21.145.145

Published: 2014

Journal Articles

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Blood (2012) 120 (21): 57.

https://doi.org/10.1182/blood.V120.21.57.57

Published: 2012

Journal Articles

Subanalysis of the StiL NHL 1–2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response.

Blood (2012) 120 (21): 2724.

https://doi.org/10.1182/blood.V120.21.2724.2724

Published: 2012

Journal Articles

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

Blood (2011) 118 (21): 4110.

https://doi.org/10.1182/blood.V118.21.4110.4110

Published: 2011

Journal Articles

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

Mathias J Rummel, MD, PhD, Ulrich Kaiser, MD, Christina Balser, Martina Beate Stauch, Wolfram Brugger, MD, PhD, Manfred Welslau, Norbert Niederle, Christoph Losem, Harald Ballo, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, MD, Julia Vereschagina, Axel Hinke, Juergen Barth

Blood (2010) 116 (21): 856.

https://doi.org/10.1182/blood.V116.21.856.856

Published: 2010

Journal Articles

Sufficient and Timely Autologous Stem Cell Harvest After Chemoimmunotherapy with Alemtuzumab In Combination with Bi-Weekly CHOP as First Line Treatment In Systemic Peripheral T-Cell Lymphomas (PTCL): a Feasibility Analysis From the First Randomized Trial In Systemic PTCL (ACT trial)

Blood (2010) 116 (21): 2395.

https://doi.org/10.1182/blood.V116.21.2395.2395

Published: 2010

Journal Articles

No Elevated Rates of Treatment-Related Myelodysplastic Syndromes and Second Solid Tumors Following Therapy with Bendamustine Compared with Other Anti-Lymphoma Regimes for Low-Grade Non-Hodgkin's Lymphoma

Mathias J Rummel, MD, PhD, Aline Tenzer, Norbert Niederle, MD, PhD, Chrisoph Losem, MD, PhD, Christina Balser, MD, PhD, Harald-E. Balló, MD, PhD, Manfred Welslau, MD, PhD, Ulrich von Grünhagen, MD, PhD, Wolfram Brugger, MD, PhD, Georg Maschmeyer, MD, PhD, Axel C. Matzdorff, MD, PhD, Arnold Ganser, MD, PhD, Eckhart Weidmann, MD, PhD, Gerhard Heil, MD, PhD, Axel Hinke, Jürgen Barth

Blood (2010) 116 (21): 3090.

https://doi.org/10.1182/blood.V116.21.3090.3090

Published: 2010

Journal Articles

Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Mathias J Rummel, MD, PhD, Norbert Niederle, Georg Maschmeyer, Andre Banat, MD, MBA, Ulrich von Gruenhagen, MD, Christoph Losem, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Harald Ballo, Eckhart Weidmann, Heinz A Duerk, Dorothea Kofahl-Krause, Fritz Roller, Juergen Barth, Dieter Hoelzer, MD, PhD, Axel Hinke, Wolfram Brugger

Blood (2009) 114 (22): 405.

https://doi.org/10.1182/blood.V114.22.405.405

Published: 2009

Journal Articles

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL)

Mathias J Rummel, Ulrich von Gruenhagen, Norbert Niederle, Harald Ballo, Eckhart Weidmann, Manfred Welslau, Gerhard Heil, Christina Balser, Heinz A Duerk, Martina Stauch, Dorothea Kofahl-Krause, Ulrich Kaiser, Wolfgang Knauf, Wolfram Brugger, MD

Blood (2008) 112 (11): 2596.

https://doi.org/10.1182/blood.V112.11.2596.2596

Published: 2008

Journal Articles

A Phase II Immunochemotherapy Study with Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) in Peripheral T-Cell Lymphomas.

Eckhart Weidmann, MD, PhD, Georg Hess, MD, STefan W. Krause, MD, PhD, Marion Subklewe, MD, Judith Kruse, MD, Martin Soekler, MD, Katja Weisel, MD, Soo-Zin Kim, MD, Martin H. Dreyling, MD, PhD, Elke Jager, MD, PhD

Blood (2006) 108 (11): 2721.

https://doi.org/10.1182/blood.V108.11.2721.2721

Published: 2006

Journal Articles

High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma.

Oliver Weigert, MD, Eckhart Weidmann, MD, Rudolf Mueck, MD, Martin Bentz, MD, Christoph von Schilling, MD, Robert Rohrberg, MD, Kathleen Jentsch-Ullrich, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, Martin H. Dreyling, MD

Blood (2006) 108 (11): 2449.

https://doi.org/10.1182/blood.V108.11.2449.2449

Published: 2006

Journal Articles

In Vivo Drug-Response in Patients with Leukemic Non-Hodgkin’s Lymphomas Is Predicted by In Vitro Chemosensitivity Testing and Gene Expression Profiling.

Kai Uwe Chow, MD, Daniel Nowak, Soo-Zin Kim, MD, Bernd Schneider, Martina Komor, Simone Boehrer, MD, Paris S. Mitrou, MD, Dieter Hoelzer, Eckhart Weidmann, Wolf-Karsten Hofmann

Blood (2004) 104 (11): 2273.

https://doi.org/10.1182/blood.V104.11.2273.2273

Published: 2004

Journal Articles

Combination Chemoimmunotherapy Using Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) Is an Effective First-Line Regimen in Peripheral T-Cell Lymphomas.

Eckhart Weidmann, MD, PhD, Georg Hess, MD, Stefan W. Krause, MD, PhD, Holger Hebart, MD, PhD, Martin Dreyling, MD, PhD, Marion Subklewe, MD, Christine Falge, MD, Kai U. Chow, MD, PhD, Elke Jaeger, MD, PhD, Parisis S. Mitrou, MD, PhD

Blood (2004) 104 (11): 2640.

https://doi.org/10.1182/blood.V104.11.2640.2640

Published: 2004

Journal Articles

Wilms Tumor Gene (wt1) mRNA Is Equally Expressed in Blast Cells From Acute Myeloid Leukemia and Normal CD34 + Progenitors

Ulrich Maurer, Eckhart Weidmann, Tunca Karakas, Dieter Hoelzer, Lothar Bergmann

Blood (1997) 90 (10): 4230–4232.

https://doi.org/10.1182/blood.V90.10.4230

Published: 1997

Journal Articles

High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome

Lothar Bergmann, Cornelius Miething, Ulrich Maurer, Jürgen Brieger, Tunca Karakas, Eckhart Weidmann, Dieter Hoelzer

Blood (1997) 90 (3): 1217–1225.

https://doi.org/10.1182/blood.V90.3.1217

Published: 1997

NARROW

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Subanalysis of the StiL NHL 1–2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response.

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

Sufficient and Timely Autologous Stem Cell Harvest After Chemoimmunotherapy with Alemtuzumab In Combination with Bi-Weekly CHOP as First Line Treatment In Systemic Peripheral T-Cell Lymphomas (PTCL): a Feasibility Analysis From the First Randomized Trial In Systemic PTCL (ACT trial)

No Elevated Rates of Treatment-Related Myelodysplastic Syndromes and Second Solid Tumors Following Therapy with Bendamustine Compared with Other Anti-Lymphoma Regimes for Low-Grade Non-Hodgkin's Lymphoma

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL)

A Phase II Immunochemotherapy Study with Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) in Peripheral T-Cell Lymphomas.

High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma.

In Vivo Drug-Response in Patients with Leukemic Non-Hodgkin’s Lymphomas Is Predicted by In Vitro Chemosensitivity Testing and Gene Expression Profiling.

Combination Chemoimmunotherapy Using Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) Is an Effective First-Line Regimen in Peripheral T-Cell Lymphomas.

Wilms Tumor Gene (wt1) mRNA Is Equally Expressed in Blast Cells From Acute Myeloid Leukemia and Normal CD34 + Progenitors

High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only